stoxline Quote Chart Rank Option Currency Glossary
Titan Pharmaceuticals, Inc. (TTNP)
7.5  0 (0%)    02-29 12:16
Open: 7.6625
High: 8
Volume: 706
Pre. Close: 7.56
Low: 7.5
Market Cap: 6(M)
Technical analysis
2024-03-01 4:55:45 PM
Short term     
Mid term     
Targets 6-month :  9.85 1-year :  11.51
Resists First :  8.43 Second :  9.85
Pivot price 7.44
Supports First :  6.46 Second :  5.25
MAs MA(5) :  7.88 MA(20) :  7.11
MA(100) :  7.14 MA(250) :  10.85
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  75.7 D(3) :  87.7
RSI RSI(14): 54.1
52-week High :  18.79 Low :  5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TTNP ] has closed below upper band by 47.3%. Bollinger Bands are 19% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.5 - 7.55 7.55 - 7.6
Low: 7.4 - 7.45 7.45 - 7.49
Close: 7.43 - 7.51 7.51 - 7.58
Company Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Headline News

Tue, 27 Feb 2024
Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at - AmericanBankingNEWS

Thu, 25 Jan 2024
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria - Yahoo Finance

Fri, 29 Dec 2023
Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Bone Bi - Benzinga

Thu, 28 Dec 2023
Titan Pharmaceuticals to conduct 1-for-20 reverse stock split (NASDAQ:TTNP) - Seeking Alpha

Thu, 28 Dec 2023
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - Yahoo Finance

Wed, 13 Dec 2023
Selling Titan Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 399730 (%)
Held by Institutions 51.1 (%)
Shares Short 4 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.35e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -51 %
Return on Assets (ttm) 525 %
Return on Equity (ttm) -61.2 %
Qtrly Rev. Growth 305000 %
Gross Profit (p.s.) -72.58
Sales Per Share -79.96
EBITDA (p.s.) 0
Qtrly Earnings Growth -8.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.1
Price to Cash Flow 0.91
Stock Dividends
Dividend 0
Forward Dividend 5160
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android